27 Jan 2025 · Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with the evolving viral threats

4 days ago · Invivyd's ongoing randomized, double-blind, Phase 1/2 clinical trial is evaluating the safety and clinical pharmacokinetic (PK) profile of VYD2311 in 40 subjects across multiple routes of administration and dose levels for a single dose, and includes VYD2311 dosed intravenously (IV), intramuscularly (IM), and subcutaneously (SC) in four cohorts of 10 patients each, …

Mission Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases. By pairing state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering techniques, we are committed to developing a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, …

3 days ago · Invivyd previously guided expectations to finish 2024 with $65 million or more in cash and cash equivalents and targeted near-term (by end of 1H 2025) profitability with existing cash and cash ...

10 Jan 2025 · Invivyd generated these new data as part of its ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.

12 Nov 2024 · Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

12 Nov 2024 · Previous disclosures from Invivyd have underlined the strong protection shown in the CANOPY clinical trial from symptomatic disease conferred by PEMGARDA over multiple waves and lineages of SARS ...

Our INVYMAB platform approach, which combines state-of-the-art viral surveillance and predictive modeling with advanced antibody discovery and engineering, is designed for the rapid, serial generation of new monoclonal antibody (mAb) candidates to address evolving viral threats.

Invivyd has demonstrated positive PEMGARDA neutralization activity against over 75% of currently circulating U.S. variants, and all prior variants, tested to date. Further, the company estimates that every clinical variant reported in the CDC COVID Tracker since the Omicron BA.1 lineage has been susceptible to pemivibart even if untested due to the consistent structural …

4 days ago · Invivyd (NASDAQ: IVVD) announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed as an alternative to COVID-19 vaccination. The trial, involving 40 subjects across multiple administration routes, showed promising results in both safety and pharmacokinetics.